| Symbol | RNA |
|---|---|
| Name | ATRIUM THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 3020 CALLAN ROAD, SAN DIEGO, CA 92121 |
| Telephone | 858-401-7900 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002093101 |
| Description | None |
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form SCHEDULE 13G - Atrium Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000902664-26-003500 <b>Size:</b> 14 KB
Read more(30% Negative) ATRIUM THERAPEUTICS, INC. (RNA) Reports Q3 2026 Financial Results
Read moreAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Read moreAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form SCHEDULE 13G - Atrium Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001346824-26-000145 <b>Size:</b> 18 KB
Read more(30% Negative) ATRIUM THERAPEUTICS, INC. (RNA) Reports Q2 2026 Financial Results
Read more